Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Independent Conference Coverage of the 2021 ASH Annual Meeting

In this activity, Srdan Verstovsek, MD, PhD, reviews key studies in myeloproliferative neoplasms (MPN), presented at the 2021 American Society of Hematology (ASH) Annual Meeting, focusing on new data improving the treatment of patients with myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN^FGFR1), polycythemia vera (PV), and myelofibrosis (MF). Amy E. DeZern, MD, MHS, will review key data from ASH 2021 in myelodysplastic syndromes (MDS), focusing on improved prognostic assessment and emerging therapeutic strategies for patients with low-risk and high-risk disease.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that also can be found here, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.